Clinical Trials Logo

Spondylitis clinical trials

View clinical trials related to Spondylitis.

Filter by:

NCT ID: NCT06220500 Recruiting - Clinical trials for Brucella Spondylitis

Radiomics Analysis Based on MRI to Detect Brucella Spondylitis

Start date: January 1, 2023
Phase:
Study type: Observational

Brucella spondylitis, an infectious spinal disease caused by the invasion of Brucella bacteria into the body. Its diagnosis relies mainly on laboratory and imaging tests. Due to the limited diagnostic ability of X-ray and CT for Brucella spondylitis, MRI has become the main diagnostic tool. In recent years, functional magnetic resonance technology has demonstrated great advantages in the diagnosis and therapeutic evaluation of brucellosis spondylitis, which can provide pathophysiologic information about the disease and is also a noninvasive and noninvasive diagnostic tool with a broader application prospect. Radiomics, an emerging approach, has also shown better diagnostic efficacy for this disease.

NCT ID: NCT06206811 Recruiting - Ulcerative Colitis Clinical Trials

Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants

Start date: February 12, 2024
Phase: Phase 1
Study type: Interventional

First-in-human study to provide an assessment of the safety, tolerability, pharmacokinetics (PK), including food effects and a drug-drug interaction, and pharmacodynamics (PD) of OD-07656 after administration of ascending single and multiple oral doses to healthy male and female participants in view of treating inflammatory bowel disease (IBD) (including Crohn's disease and ulcerative colitis), Blau syndrome, and spondyloarthritis

NCT ID: NCT06198985 Not yet recruiting - Clinical trials for Ankylosing Spondylitis

The Effect of Dynamic Balance Exercises on Balance in Patients With Ankylosing Spondylitis.

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The aim of the study is to investigate the effect of dynamic balance exercises added to current medical treatment on balance in patients with ankylosing spondylitis.

NCT ID: NCT06197009 Not yet recruiting - Clinical trials for Axial Spondyloarthritis

Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SCT650C in patients with Axial Spondyloarthritis

NCT ID: NCT06185712 Completed - Clinical trials for Ankylosing Spondylitis

Patient Education in Ankylosing Spondylitis

Start date: August 1, 2020
Phase: N/A
Study type: Interventional

This study was carried out to investigate the effect of a nurse-led disease management education program in AS on patient compliance, disease activity, functional capacity, kinesiophobia, and quality of life. A total of 122 patients diagnosed with AS according to the modified New York criteria were included in the study. The intervention group received nurse-led individualized disease management education. In the control group, no interventions were performed other than routine clinical procedures.

NCT ID: NCT06138717 Recruiting - Clinical trials for Axial Spondyloarthritis and Ankylosing Spondylitis

The Effect of Aerobic Exercises and Yoga Exercises in Axial Spondyloarthritis

Start date: November 18, 2022
Phase: N/A
Study type: Interventional

Axial Spondyloarthritis (AxSpA), mainly affecting the axial skeleton and sacroiliac joints, is a chronic, systemic, inflammatory disease that causes structural and functional disorders. Exercise has a significant role to play in managing treatments. This study aimed to determine the effect of yoga-based exercises combined with aerobic exercise on spinal mobility, disease activity and aerobic capacity in AxSpA.

NCT ID: NCT06114407 Recruiting - Clinical trials for Spondyloarthritis, Axial

Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib

Start date: October 30, 2023
Phase: Phase 2
Study type: Interventional

Axial Spondylarthritis (ax-SpA) is an important cause of inflammatory back pain in young adults. Janus kinase inhibitors (JAKi) has been approved for treatment of ax-SpA. Tofacitinib and baricitinib are drugs from same family (JAKi). Baricitinib is relatively less expensive than Tofacitinib. The goal of this non-inferiority clinical trial is to learn about the efficacy of baricitinib in refractory axial spondyloarthritis ( ax-SpA) and to compare its effect with that of tofacitinib. The main questions it aims to answer are: 1. Is baricitinib 4 mg effective in refractory ax-SpA? 2. Is baricitinib non-inferior to tofacitinib in refractory ax-SpA? Participants (treatment group, 92 patients) will be treated with baricitinib 2 mg twice daily for 12 weeks. Ninety two patients getting tofacitinib 10 mg/day (comparison group) will be taken as historical control from another study on the efficacy of tofacitinib in refractory ax-SpA?

NCT ID: NCT06112665 Not yet recruiting - Clinical trials for Axial Spondyloarthritis

ToFAcitinib in Early Active Axial SpondyloarThritis:

FASTLANE
Start date: November 10, 2023
Phase: Phase 4
Study type: Interventional

This is a phase IV, multicentre, randomized, double-blind, placebo-controlled study designed to compare the efficacy and safety of tofacitinib versus placebo (on a background of an NSAID) over 16 weeks of treatment and 4 weeks of safety follow-up in subjects with early active axSpA and inadequate response to at least one NSAID, with objective signs of inflammation.

NCT ID: NCT06094686 Completed - Clinical trials for Ankylosing Spondylitis

Epicardial Adipose Tissue Thickness and the Related Factors in Patients With Ankylosing Spondylitis

Start date: August 1, 2015
Phase:
Study type: Observational

The aim of this study was to assess the EATT and the related factors in patients with AS and to compare the results with that of the healthy controls'

NCT ID: NCT06094673 Completed - Clinical trials for Ankylosing Spondylitis

The Relationship Between Systemic Immune Inflammation Index and Disease Activity in Patients With Ankylosing Spondylitis

Start date: June 1, 2023
Phase:
Study type: Observational [Patient Registry]

In this study, the aim was to investigate the relationship between SII and other laboratory parameters with disease activity in AS patients and to discuss its usability in the follow-up and treatment process.